A company 1,000-ton NMN industrialization project was approved

[API] Recently, Jilin GSH Bio-technology Co., Ltd. enzymatic production β-nicotinamide mononucleotide (NMN) and industrialization project have been approved and announced on relevant websites.

The NMN industrialization project with a total investment of 580 million and an annual output of 1,000 tons has been approved
The NMN industrialization project with a total investment of 580 million and an annual output of 1,000 tons has been approved

According to the approval announcement, the project designed to produce 1,000 tons of β-nicotinamide mononucleotide per year after completion.

Founded in 2017, GSH Bio-tech is an innovative high-tech enterprise with enzyme catalysis technology in the field of synthetic biology as its core and cross-application of multidisciplinary technologies. The main products include glutathione (GSH), β-nicotinamide mononucleotide and citicoline sodium (CDPC) and other APIs.

NMN the most direct precursor of NAD+. naturally occurring substance in the human body and also found in many foods.

Nicotinamide Mononucleotide molecules can easily pass through the cell membrane and enter the cell interior, which can increase the content of NMN in the tissue, thereby rapidly increasing the level of NMN. NAD+ levels in the body.

NMN powder
NMN powder

According to research, NAD+ widely involved in a variety of basic physiological activities in the organism,

thereby intervening in key cellular functions such as energy metabolism, DNA repair, genetic modification, inflammation, biological rhythms, and stress resistance.

Because multiple anti-aging functions, given aura “elixir of youth”!

mainly promoted used in four major fields: food health care, beauty care, biomedicine, and animal nutrition. It has huge room for imagination and has attracted many companies to deploy.

NMN main enterprises include:

GSHWORLD, GSH Bio-Tech, Geneport, Yinfu, Jindawei, Shangke Biotechnology, Bangtai Biotechnology, Jilin Biao (Nanjing Nuoyun), Yaben Chemical, Pilot Biotechnology, Yikelai, Fujian Ruiboao, Jiangxi Haiwen wait.

According to industry insiders, due to the particularity of product sales and the existence of underwater operations, the current total NMN market demand is a mystery, and it is difficult to say how large it will be in hundreds or thousands of tons.

Regulatory aspect, United States:

NMN not considered a dietary supplement but considered a drug or drug ingredient that requires FDA approval. Europe: Not approved as a food or health product ingredient. China: No administrative license granted as a new food additive. Japan: Include NMN in the list of food ingredients.

NMN has attracted the deployment of many companies. The author has summarized several reasons. Welcome to exchange and discuss!

  • “Rapid replication” of domestic synthetic biology.
  • There is huge room for imagination in future applications in multiple fields, and it can gain favor from the capital market.
  • With strong consumption attributes, no matter how high the NMN raw materials are, To C prices are stable.

It looks like this is much better than medicine!